Modified Single-Incision Plus One-Port Versus Conventional Five-Port Laparoscopic Pancreaticoduodenectomy for Nonpancreatic Periampullary Adenocarcinomas

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-75
SponsorNanfang Hospital, Southern Medical University

About this trial

This multicenter, randomized, controlled, non-inferiority trial will compare modified single-incision plus one-port laparoscopic pancreaticoduodenectomy (mSILPD+1) with conventional five-port laparoscopic pancreaticoduodenectomy (CLPD) in adults with histologically confirmed or highly suspected non-pancreatic periampullary carcinoma who are candidates for pancreaticoduodenectomy. A total of 232 participants will be randomly assigned in a 1:1 ratio. Outcome assessors who adjudicate complications and interpret imaging will be masked to treatment assignment. The primary outcomes are all-cause mortality within 90 days after surgery and overall survival at 1 year after surgery. Secondary outcomes will assess postoperative complications, surgical performance, postoperative recovery, disease-free survival, quality of life, and health-care costs.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age 18 years or older and younger than 75 years.

Histopathologically confirmed non-pancreatic periampullary carcinoma, or a high clinical suspicion of non-pancreatic periampullary carcinoma when preoperative pathological confirmation is unavailable.

Determined by preoperative multidisciplinary team evaluation to require pancreaticoduodenectomy.

Able to understand and comply with study procedures.

Disqualifiers

Distant metastasis, including peritoneal, hepatic, distant lymph node, or other organ metastasis.

Requirement for distal, central, or total pancreatectomy, or another palliative procedure.

Preoperative American Society of Anesthesiologists physical status classification of 4 or higher.

Concurrent malignancy other than the target cancer.

Trial design

Design model

Parallel

Treatments tested in this trial

  • Modified Single Incision plus one-port Laparoscopic Pancreaticoduodenectomy

    Procedure/Surgery

    A pancreaticoduodenectomy performed through a 60- to 80-mm periumbilical single-incision access platform containing three trocars, with one additional 12-mm laparoscopic port. Resection and reconstruction are performed according to the standardized multicenter operative protocol.

  • Conventional Laparoscopic Pancreaticoduodenectomy

    Procedure/Surgery

    A conventional laparoscopic pancreaticoduodenectomy performed using five trocar ports, followed by resection and reconstruction according to the standardized multicenter operative protocol.

Treatment groups

232 Participants
are divided into 2 treatment groups
Group A: Modified Single-Incision Plus One-Port Laparoscopic PancreaticoduodenectomyExperimental treatment 1 intervention
Group B: Conventional Five-Port Laparoscopic PancreaticoduodenectomyActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

Overall Survival Rate at 1 Year After Surgery

Time frame
From the date of surgery to 1 year after surgery
2

All-Cause Mortality Within 90 Days After Surgery

Time frame
From surgery through 90 days after surgery

Secondary outcomes

1

Overall Postoperative Complication Rate Within 30 Days

Time frame
From surgery through 30 days after surgery
2

R0 Resection Rate

R0 resection rate, defined as the percentage of subjects without microscopic residual tumor on surgical margins based on final postoperative pathological assessment.

Time frame
At final postoperative pathological assessment, up to 30 days after surgery
3

Operative Time

Time frame
During the index surgery
4

Disease-Free Survival Rate at 1 Year After Surgery

Time frame
From the date of surgery to 1 year after surgery

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.